Relapsing Multiple Sclerosis Clinical Trial
Official title:
An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04121065 -
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)
|
||
| Active, not recruiting |
NCT03996291 -
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
|
Phase 2 | |
| Recruiting |
NCT04510220 -
9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 3 | |
| Terminated |
NCT02241785 -
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies
|
Phase 4 | |
| Completed |
NCT02792218 -
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT01412333 -
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT03257358 -
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
|
Phase 4 | |
| Completed |
NCT01628393 -
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT04626921 -
A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT02234869 -
Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
|
Phase 4 | |
| Withdrawn |
NCT05077956 -
Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis
|
||
| Active, not recruiting |
NCT04486716 -
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Recruiting |
NCT04121403 -
Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)
|
Phase 3 | |
| Recruiting |
NCT05809986 -
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
|
||
| Terminated |
NCT00988052 -
A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
|
Phase 3 | |
| Active, not recruiting |
NCT05232825 -
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
|
Phase 3 | |
| Terminated |
NCT01047319 -
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT04847596 -
A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
|
||
| Completed |
NCT01127750 -
Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients
|
Phase 3 | |
| Completed |
NCT01006941 -
Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study
|
Phase 2 |